ClinicalTrials.gg
CompletedNCT05466422Updated Sep 3, 2026Results posted

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

A Phase 1 interventional study of MK-2214 and Placebo in Alzheimer Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 12 sites in United States. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Alzheimer Disease by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Merck & Co., Inc.

Enrollment
15th of 29
34 · median 34
Started
2022
with 2 others
Phase 1
18 of 31
none open now
Registered
26th of 31
by date

Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, this one is the 15th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2022, is one of 18 in phase 1, and was the 26th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 31 studies in Alzheimer Disease by Merck & Co., Inc is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Alzheimer Disease by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-2214 in adults with mild cognitive impairment or mild-to-moderate Alzheimer's Disease. The primary hypothesis (Part 1) is that at a generally well-tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is >0.3 nanomolar

Read the detailed description

As specified by Phase 1 flexible language in the protocol, modifications to the dose or dosing regimen could be made to achieve the scientific goals of the trial objectives and/or ensure appropriate safety of the trial participants. The proposed doses could be adjusted based on evaluation of safety, tolerability, and pharmacokinetic data observed in previous panels.

Part 2 was optional and was not conducted.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Participant is in overall good health based on medical history and laboratory safety tests
  • between 18.5 and 35 kg/m\^2

Part 1 (Mild Cognitive Impairment [MCI] and Mild-to-Moderate Alzheimer's Disease [AD]) Only:

  • History of cognitive and functional decline with gradual onset and slow progression for at least one year before Screening
  • (MMSE) score >12 at the prestudy visit
  • Modified Hachinski Ischemic Score (MHIS) \<4 at the prestudy visit

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Based on clinical interview and Columbia-Suicide Severity Rating Scale (C-SSRS), has reported suicidal ideation with intent, with or without a plan or method
  • History of unstable or poorly controlled endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, renal, respiratory, or genitourinary abnormalities or diseases
  • History of active neurological disease (except for AD or MCI for participants in Part 1)
  • History of clinically significant active disease requiring ongoing systemic therapy
  • History of cancer ()
  • History of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food
  • Positive test(s) for Surface Antigen (HBsAg), antibodies or (HIV)
  • Has had a major surgery and/or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy visit
  • Has a to lumbar dural puncture, such as coagulopathy, concomitant anticoagulation beyond low dose aspirin, thrombocytopenia, or other factors that could preclude safe lumbar puncture
  • Currently receiving or has received aducanumab or another anti-amyloid therapy within the last 6 months
  • Has a history of receiving biological therapy within 3 months or 5 half-lives (whichever is longer) or any human immunoglobulin preparation within the last year
  • Has received any non- starting from 14 days prior to first study intervention or is scheduled to receive any non-live vaccine through 14 days following the final dose of study intervention. Exception: coronavirus disease of 2019 (COVID-19) and influenza vaccines may be administered
  • Is receiving systemic immunosuppression, including exceeding physiologic replacement doses
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Panel A: MK-2214 20 mg

    Participants were randomized to receive MK-2214 20 mg as an intravenous (IV) infusion every month (qm) for 3 months (on Days 1, 29, and 57).

    Biological: MK-2214

  • Experimental
    Panel B: MK-2214 100 mg

    Participants were randomized to receive MK-2214 100 mg as an IV infusion qm for 3 months (on Days 1, 29, and 57).

    Biological: MK-2214

  • Experimental
    Panel C: MK-2214 500 mg

    Participants were randomized to receive MK-2214 500 mg as an IV infusion qm for 3 months (on Days 1, 29, and 57).

    Biological: MK-2214

  • Experimental
    Panel D: MK-2214 2000 mg

    Participants were randomized to receive MK-2214 2000 mg as an IV infusion qm for 3 months (on Days 1, 29, and 57).

    Biological: MK-2214

  • Placebo comparator
    Placebo

    Participants were randomized to receive placebo as an IV infusion qm for 3 months (on Days 1, 29, and 57).

    Drug: Placebo

Interventions

  • BiologicalMK-2214

    IV infusion

  • DrugPlacebo

    IV infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced at least one AE was reported.

    Time frame: Up to approximately 297 days

  2. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE was reported.

    Time frame: Up to approximately 57 days

  3. Area Under the Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of MK-2214 in Serum After First Dose (Day 1)

    AUC0-28 was defined as the area under the concentration-time curve from time 0 to 28 days of MK-2214 in serum. Blood samples were collected at prespecified time points to determine AUC0-28 of MK-2214 in serum after first dose (Day 1).

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29

  4. AUC0-28 of MK-2214 in Serum After Third Dose (Day 57)

    AUC0-28 was defined as the area under the concentration-time curve from time 0 to 28 days of MK-2214 in serum. Blood samples were collected at prespecified time points to determine AUC0-28 of MK-2214 in serum after third dose (Day 57).

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297

  5. Maximum Serum Concentration (Cmax) of MK-2214 After First Dose (Day 1)

    Cmax was defined as the maximum concentration of MK-2214 observed in serum. Blood samples were collected at prespecified time points to determine Cmax of MK-2214 after first dose (Day 1).

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29

  6. Cmax of MK-2214 After Third Dose (Day 57)

    Cmax was defined as the maximum concentration of MK-2214 observed in serum. Blood samples were collected at prespecified time points to determine Cmax of MK-2214 after third dose (Day 57).

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297

  7. Time of Maximum Serum Concentration (Tmax) of MK-2214 After First Dose (Day 1)

    Tmax was defined as the time to maximum serum concentration of MK-2214. Blood samples were collected at prespecified time points to determine Tmax of MK-2214 in serum after first dose (Day 1).

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29

  8. Tmax of MK-2214 After Third Dose (Day 57)

    Tmax was defined as the time to maximum serum concentration of MK-2214. Blood samples were collected at prespecified time points to determine Tmax of MK-2214 in serum after third dose (Day 57).

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297

  9. Apparent Half-Life (T1/2) of MK-2214 in Serum After Third Dose (Day 57)

    T1/2 was defined as the apparent half-life of MK-2214 observed in serum. Blood samples were collected at prespecified time points to determine t1/2 of MK-2214 in serum after third dose (Day 57).

    Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297

  10. Concentration of MK-2214 in Cerebrospinal Fluid (CSF) at Day 85

    Concentration of MK-2214 in CSF was defined as the CSF exposure of MK-2214. A CSF sample was to be collected on Day 85.

    Time frame: Day 85

  11. Free Phospho-Tau Concentration in CSF

    Concentration of free phospo-tau in CSF was defined as free phospho-tau levels in CSF after study treatment administration (MK-2214 or placebo). A CSF sample was to be collected on Day 85.

    Time frame: Day 85

07

Results

Posted Sep 3, 2026

Participant flow

Participant flow — Overall Study
MilestonePanel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mgPlacebo
Started76669
Completed66657
Not completed10012
Withdrew: Lost to follow-up10000
Withdrew: Sponsor decision00012

Outcome measures

PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced at least one AE was reported.

Time frame:
Up to approximately 297 days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPanel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mgPlacebo
Number of Participants Who Experienced an Adverse Event (AE)55457
PrimaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE was reported.

Time frame:
Up to approximately 57 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsPanel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mgPlacebo
Number of Participants Who Discontinued Study Treatment Due to an AE00001
PrimaryArea Under the Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of MK-2214 in Serum After First Dose (Day 1)

AUC0-28 was defined as the area under the concentration-time curve from time 0 to 28 days of MK-2214 in serum. Blood samples were collected at prespecified time points to determine AUC0-28 of MK-2214 in serum after first dose (Day 1).

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29
Reported as:
Geometric mean · h*µg/L
Area Under the Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of MK-2214 in Serum After First Dose (Day 1)
h*µg/LPanel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mg
Area Under the Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of MK-2214 in Serum After First Dose (Day 1)1090000 (855000 to 1390000)5730000 (4410000 to 7440000)25000000 (19300000 to 32500000)200000 (154000 to 259000)
PrimaryAUC0-28 of MK-2214 in Serum After Third Dose (Day 57)

AUC0-28 was defined as the area under the concentration-time curve from time 0 to 28 days of MK-2214 in serum. Blood samples were collected at prespecified time points to determine AUC0-28 of MK-2214 in serum after third dose (Day 57).

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
Reported as:
Geometric mean · h*µg/L
AUC0-28 of MK-2214 in Serum After Third Dose (Day 57)
h*µg/LPanel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mg
AUC0-28 of MK-2214 in Serum After Third Dose (Day 57)2030000 (1580000 to 2610000)13000000 (9990000 to 16800000)49800000 (38300000 to 64600000)325000 (247000 to 428000)
PrimaryMaximum Serum Concentration (Cmax) of MK-2214 After First Dose (Day 1)

Cmax was defined as the maximum concentration of MK-2214 observed in serum. Blood samples were collected at prespecified time points to determine Cmax of MK-2214 after first dose (Day 1).

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29
Reported as:
Geometric mean · µg/L
Maximum Serum Concentration (Cmax) of MK-2214 After First Dose (Day 1)
µg/LPanel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mg
Maximum Serum Concentration (Cmax) of MK-2214 After First Dose (Day 1)5360 (3960 to 7250)29600 (21400 to 41100)129000 (93200 to 179000)980 (707 to 1360)
PrimaryCmax of MK-2214 After Third Dose (Day 57)

Cmax was defined as the maximum concentration of MK-2214 observed in serum. Blood samples were collected at prespecified time points to determine Cmax of MK-2214 after third dose (Day 57).

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
Reported as:
Geometric mean · µg/L
Cmax of MK-2214 After Third Dose (Day 57)
µg/LPanel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mg
Cmax of MK-2214 After Third Dose (Day 57)7300 (5280 to 10100)39400 (28400 to 54600)167000 (120000 to 231000)1200 (845 to 1710)
PrimaryTime of Maximum Serum Concentration (Tmax) of MK-2214 After First Dose (Day 1)

Tmax was defined as the time to maximum serum concentration of MK-2214. Blood samples were collected at prespecified time points to determine Tmax of MK-2214 in serum after first dose (Day 1).

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29
Reported as:
Median · hr
Time of Maximum Serum Concentration (Tmax) of MK-2214 After First Dose (Day 1)
hrPanel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mg
Time of Maximum Serum Concentration (Tmax) of MK-2214 After First Dose (Day 1)1.00 (0.50 to 23.97)1.29 (0.53 to 2.05)1.01 (0.55 to 12.02)1.03 (0.12 to 2.00)
PrimaryTmax of MK-2214 After Third Dose (Day 57)

Tmax was defined as the time to maximum serum concentration of MK-2214. Blood samples were collected at prespecified time points to determine Tmax of MK-2214 in serum after third dose (Day 57).

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
Reported as:
Median · hr
Tmax of MK-2214 After Third Dose (Day 57)
hrPanel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mg
Tmax of MK-2214 After Third Dose (Day 57)1.03 (0.53 to 3.98)3.99 (1.35 to 672.27)2.02 (0.52 to 4.07)1.00 (0.12 to 4.03)
PrimaryApparent Half-Life (T1/2) of MK-2214 in Serum After Third Dose (Day 57)

T1/2 was defined as the apparent half-life of MK-2214 observed in serum. Blood samples were collected at prespecified time points to determine t1/2 of MK-2214 in serum after third dose (Day 57).

Time frame:
Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
Reported as:
Geometric mean · hr
Apparent Half-Life (T1/2) of MK-2214 in Serum After Third Dose (Day 57)
hrPanel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mg
Apparent Half-Life (T1/2) of MK-2214 in Serum After Third Dose (Day 57)1964.6 ± 23.11519.5 ± 41.82016.5 ± 18.02204.6 ± 16.6
PrimaryConcentration of MK-2214 in Cerebrospinal Fluid (CSF) at Day 85

Concentration of MK-2214 in CSF was defined as the CSF exposure of MK-2214. A CSF sample was to be collected on Day 85.

Time frame:
Day 85
Reported as:
Geometric mean · nM
Concentration of MK-2214 in Cerebrospinal Fluid (CSF) at Day 85
nMPanel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mg
Concentration of MK-2214 in Cerebrospinal Fluid (CSF) at Day 850.0487 (0.0258 to 0.0920)0.378 (0.200 to 0.714)1.13 (0.596 to 2.12)0.00655 (0.00347 to 0.0124)
Statistical analysis
  • Panel A: MK-2214 20 mg · Posterior probability (%): 1Posterior probability that the true geometric mean (GM) MK-2214 CSF concentration at Day 85 (C85d) \>0.3 nanomolar (nM).
  • Panel B: MK-2214 100 mg · Posterior probability (%): 76Posterior probability that the true GM MK-2214 CSF C85d \>0.3 nM.
  • Panel C: MK-2214 500 mg · Posterior probability (%): 99Posterior probability that the true GM MK-2214 CSF C85d \>0.3 nM.
  • Panel D: MK-2214 4 mg · Posterior probability (%): 1Posterior probability that the true GM MK-2214 CSF C85d \>0.3 nM.
PrimaryFree Phospho-Tau Concentration in CSF

Concentration of free phospo-tau in CSF was defined as free phospho-tau levels in CSF after study treatment administration (MK-2214 or placebo). A CSF sample was to be collected on Day 85.

Time frame:
Day 85
Reported as:
Mean · fM
Free Phospho-Tau Concentration in CSF
fMPanel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mgPlacebo
Free Phospho-Tau Concentration in CSF4.1 ± 0.004.1 ± 0.004.1 ± 0.00—13 ± 3.2

Adverse events

Collected over Up to approximately 297 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-2214 20 mg0/7 (0%)0/7 (0%)5/7 (71.4%)
MK-2214 100 mg0/6 (0%)1/6 (16.7%)5/6 (83.3%)
MK-2214 500 mg0/6 (0%)2/6 (33.3%)4/6 (66.7%)
MK-2214 4 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Placebo0/9 (0%)1/9 (11.1%)7/9 (77.8%)
MK-2214 Total0/25 (0%)3/25 (12%)19/25 (76%)
Most frequent serious events
Most frequent serious events
EventMK-2214 20 mgMK-2214 100 mgMK-2214 500 mgMK-2214 4 mgPlaceboMK-2214 Total
CholelithiasisHepatobiliary disorders0/70/61/60/60/91/25
Hepatic lesionHepatobiliary disorders0/71/60/60/60/91/25
Portal vein thrombosisHepatobiliary disorders0/71/60/60/60/91/25
OsteomyelitisInfections and infestations0/70/61/60/60/91/25
SepsisInfections and infestations0/71/60/60/60/91/25
DehydrationMetabolism and nutrition disorders0/71/60/60/60/91/25
Pleural effusionRespiratory, thoracic and mediastinal disorders0/71/60/60/60/91/25
SeizureNervous system disorders0/70/60/60/61/90/25
Most frequent other events
Showing 10 of 50
Most frequent other events
EventMK-2214 20 mgMK-2214 100 mgMK-2214 500 mgMK-2214 4 mgPlaceboMK-2214 Total
HeadacheNervous system disorders1/71/63/62/62/97/25
Back painMusculoskeletal and connective tissue disorders1/70/60/62/60/93/25
DizzinessNervous system disorders0/71/60/62/61/93/25
Urinary tract infectionInfections and infestations0/70/61/60/62/91/25
AnaemiaBlood and lymphatic system disorders0/71/60/60/60/91/25
Normocytic anaemiaBlood and lymphatic system disorders0/71/60/60/60/91/25
DyspepsiaGastrointestinal disorders0/71/60/60/60/91/25
NauseaGastrointestinal disorders0/70/61/60/60/91/25
FatigueGeneral disorders0/70/60/61/60/91/25
Generalised oedemaGeneral disorders0/71/60/60/60/91/25

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Panel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mgPlaceboTotal
Mean73.1 ± 9.568.3 ± 4.371.2 ± 8.573.3 ± 3.168.9 ± 8.270.9 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)Panel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mgPlaceboTotal
Female3434418
Male4232516
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Panel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mgPlaceboTotal
Hispanic or Latino3301411
Not Hispanic or Latino4365523
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Panel A: MK-2214 20 mgPanel B: MK-2214 100 mgPanel C: MK-2214 500 mgPanel D: MK-2214 4 mgPlaceboTotal
American Indian or Alaska Native000000
Asian000101
Native Hawaiian or Other Pacific Islander000000
Black or African American121105
White6454928
More than one race000000
Unknown or Not Reported000000
08

Study locations

12 sites
  • California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0007)
    Glendale, California 91206, United States
  • Collaborative Neuroscience Research, LLC ( Site 0009)
    Los Alamitos, California 90720, United States
  • NRC Research Institute ( Site 0015)
    Orange, California 92868, United States
  • Velocity Clinical Research, Hallandale Beach ( Site 0001)
    Hallandale, Florida 33009, United States
  • Research Centers of America ( Hollywood ) ( Site 0004)
    Hollywood, Florida 33024, United States
  • K2 Medical Research ( Site 0005)
    Maitland, Florida 32751, United States
  • Charter Research - Winter Park ( Site 0012)
    Orlando, Florida 32803, United States
  • Progressive Medical Research-Alzheimer's Team ( Site 0013)
    Port Orange, Florida 32127, United States
  • Charter Research - Lady Lake ( Site 0011)
    The Villages, Florida 32162, United States
  • CenExel iResearch, LLC ( Site 0002)
    Decatur, Georgia 30030, United States
  • Global Medical Institutes LLC; Princeton Medical Institute ( Site 0003)
    Princeton, New Jersey 08540, United States
  • Neuro-Behavioral Clinical Research ( Site 0016)
    North Canton, Ohio 44720, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jul 2025, 33 months.

Results were first posted in Sep 2026, 1 year 2 months after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 33 months is above that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2022
First posted
Jul 20, 2022
StartActual
Sep 20, 2022
Primary completionActual
Jul 3, 2025
CompletionActual
Jul 3, 2025
Results first posted
Sep 3, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05466422
Responsible party
Sponsor
First posted
Jul 20, 2022
Start date
Sep 20, 2022
Primary completion
Jul 3, 2025
Completion
Jul 3, 2025
Results posted
Sep 3, 2026
Last update
Sep 3, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion